Document is current
Any future updates will be listed below
-
Authors
Bartlett, Jeremy A. https://orcid.org/0009-0001-8229-502X
Culver, Natalie
Santangelo, Matt
Prpich, Andrew
Long, Erica
Sagawa, Kazuko https://orcid.org/0009-0006-1834-2537
Shanker, Ravi
Xu, Huiping
Wilner, Keith https://orcid.org/0000-0002-2276-7865
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00939770 at ClinicalTrials.govnct01606878 at ClinicalTrials.govDocuments that mention this clinical trial
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium
https://doi.org/10.1007/s00280-016-3220-6
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
nct02006277 at ClinicalTrials.govDocuments that mention this clinical trial
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
nct03137134 at ClinicalTrials.govDocuments that mention this clinical trial
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
nct03978143 at ClinicalTrials.govDocuments that mention this clinical trial
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
nct04856293 at ClinicalTrials.govDocuments that mention this clinical trial
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
Documents that mention this clinical trial
Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation
https://doi.org/10.1007/s40290-026-00604-2
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 2 March 2026
First Online: 1 April 2026
Declarations
:
: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Huiping Xu, and Keith Wilner are employees of and own stocks in Pfizer. Ravi Shanker was an employee of Pfizer at the time of this study.
: Upon request and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Conceptualization: Jeremy A. Bartlett, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Methodology: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Data curation: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Formal analysis and investigation: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Writing—original draft preparation: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Writing—review and editing: Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, and Keith Wilner; Supervision: Jeremy A. Bartlett, Ravi Shanker, Huiping Xu, and Keith Wilner. All authors read and approved the final version of the manuscript.
